Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation
International Journal of Urology · 2026
DOI: 10.1111/iju.70591 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Kodai Abe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gunma University Graduate School of Medicine & Gunma University Hospital, Maebashi, Gunma, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Benzamides, Nitriles, Radium. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Radium‐223 dichloride (Ra‐223) is an effective treatment for metastatic castration‐resistant prostate cancer (mCRPC) with bone metastases. However, predictive factors associated with treatment efficacy remain unclear. This study evaluated prognostic factors associated with the efficacy of Ra‐223 and investigated outcomes according to enzalutamide (ENZ) combination patterns.
Methods
We retrospectively analyzed 34 patients with mCRPC treated with Ra‐223 between 2016 and 2024. Progression‐free survival (PFS) and overall survival (OS) were evaluated according to time to CRPC, pre‐treatment prostate‐specific antigen (PSA), PSA doubling time (PSADT), metastatic burden, and ENZ treatment patterns. Cutoff values were determined using the Contal–O'Quigley method. This study was approved by the Institutional Review Board of Gunma University (Approval No. 1662).
Results
The median time to CRPC, pre‐treatment PSA level, and PSADT were 17 months, 6.2 ng/mL, and 2.2 months, respectively. Shorter time to CRPC (≤ 19 months), higher pre‐treatment PSA (> 2.67 ng/mL), and shorter PSADT (≤ 2 months) were significantly associated with shorter PFS. Patients with ≥ 4 bone metastatic regions had significantly worse OS than those with ≤ 3 regions. Among the ENZ treatment patterns, continuous ENZ administration combined with Ra‐223 was associated with significantly longer PFS than discontinuation of ENZ.
Conclusions
Time to CRPC, pre‐treatment PSA, and PSADT may represent potentially useful candidate markers for identifying patients more likely to benefit from Ra‐223 therapy. Continued ENZ administration during Ra‐223 therapy was associated with favorable PFS in selected patients; however, this finding should be considered exploratory and requires validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Gunma University Graduate School of Medicine & Gunma University Hospital, Maebashi, Gunma, Japan.
- Department of Urology, Tomioka General Hospital, Tomioka, Gunma, Japan.
ORCID-Profile: Kodai Abe, Yoshiyuki Miyazawa, Akira Ohtsu, Seiji Arai, Yoshitaka Sekine, Kazuhiro Suzuki
Zitieren
APA
Abe, K., Miyazawa, Y., Nakazawa, S., Onose, M., Maeno, Y., Tsuji, Y., Kanayama, A., Ohtsu, A., Fujizuka, Y., Arai, S., Nomura, M., Sekine, Y., Koike, H., Matsui, H., & Suzuki, K. (2026). Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation. International Journal of Urology. https://doi.org/10.1111/iju.70591
Vancouver
Abe K, Miyazawa Y, Nakazawa S, Onose M, Maeno Y, Tsuji Y, et al. Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation. International Journal of Urology. 2026. doi:10.1111/iju.70591
BibTeX
@article{Abe2026,
author = {Abe, Kodai and Miyazawa, Yoshiyuki and Nakazawa, Shun and Onose, Mai and Maeno, Yuta and Tsuji, Yusuke and Kanayama, Azusa and Ohtsu, Akira and Fujizuka, Yuji and Arai, Seiji and Nomura, Masashi and Sekine, Yoshitaka and Koike, Hidekazu and Matsui, Hiroshi and Suzuki, Kazuhiro},
title = {Real‐World Outcomes of Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer: Predictive Value of PSA Doubling Time and Enzalutamide Continuation},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70591}
}
EUVIMED